NERVGEN PHARMA CORP.
Research NERVGEN PHARMA CORP. (9UA) on Bullrun: market cap EUR 161.28M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker9UA
- ExchangeF
- CountryCanada
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 161.28M
- Financial periodFY2025
- RevenueCAD 0
- Net income-CAD 44.12M
- Free cash flow-CAD 19.50M
Valuation Snapshot
latest market cap is EUR 161.28M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CAD 0 | -CAD 44.12M | -CAD 19.50M | n/a | n/a | CAD 22.07M | CAD 8.37K | CAD 3.48M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | EUR 161.28M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About NERVGEN PHARMA CORP.
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is NERVGEN PHARMA CORP.'s market cap?
NERVGEN PHARMA CORP.'s market capitalization is EUR 161.28M.
What does NERVGEN PHARMA CORP. do?
NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study. NervGen Pharma Corp.